Display options
Cite
Willerson JT, Buja LM. Potential of combined thromboxane A2 and serotonin antagonists to prevent the development of unstable angina and acute myocardial infarction. Tex Heart Inst J. 1990;17(3):157-64
Willerson, J. T., & Buja, L. M. (1990). Potential of combined thromboxane A2 and serotonin antagonists to prevent the development of unstable angina and acute myocardial infarction. Texas Heart Institute journal, 17(3), 157-64.
Willerson, J T, and Buja, L M. "Potential of combined thromboxane A2 and serotonin antagonists to prevent the development of unstable angina and acute myocardial infarction." Texas Heart Institute journal vol. 17,3 (1990): 157-64.
Willerson JT, Buja LM. Potential of combined thromboxane A2 and serotonin antagonists to prevent the development of unstable angina and acute myocardial infarction. Tex Heart Inst J. 1990;17(3):157-64. PMID: 15227166; PMCID: PMC324912.
Copy Download .nbib Format: NLM
Share it on

Tex Heart Inst J. 1990;17(3):157-64.

Potential of combined thromboxane A2 and serotonin antagonists to prevent the development of unstable angina and acute myocardial infarction.

Texas Heart Institute journal

J T Willerson, L M Buja

Affiliations

  1. The Department of Internal Medicine, University of Texas Medical School at Houston, Houston, Texas, USA.

PMID: 15227166 PMCID: PMC324912

Abstract

We have previously speculated that the abrupt conversion from chronic stable angina to unstable angina and the subsequent progression to acute myocardial infarction may result from myocardial ischemia caused by progressive platelet aggregation and dynamic coronary vasoconstriction. In turn, platelet aggregation and dynamic vasoconstriction probably result from the local accumulation of thromboxane A(2) and serotonin at sites of coronary artery stenosis and endothelial injury; they may also result from relative decreases in the local concentrations of endothelium-derived vasodilators and inhibitors of platelet aggregation, such as endothelium-derived relaxing factors and prostacyclin. Because of severe reductions in coronary blood flow caused by these mechanisms, platelet aggregation may increase, and an occlusive thrombus-composed of platelets, leukocytes, and red blood cells in a fibrin mesh-may develop. When coronary arteries are occluded or narrowed by these mechanisms for a sufficient time, the result may be myocardial necrosis, electrical instability, or sudden death. With respect to the process of coronary artery thrombosis and vasoconstriction, we believe that unstable angina and acute myocardial infarction are 2 elements in a continuum. When platelet aggregation or dynamic vasoconstriction at sites of endothelial injury and coronary stenosis is brief, unstable angina or non-Q-wave infarction may occur. When coronary obstruction by these mechanisms is prolonged for several hours, however, Q-wave myocardial infarction results. Future clinical studies should provide further insights into these and additional mediators and mechanisms that may effect the abrupt transition from chronic to acute coronary disease syndromes in human beings.

References

  1. Lancet. 1977 Apr 2;1(8014):713-7 - PubMed
  2. Circulation. 1984 Jun;69(6):1161-70 - PubMed
  3. N Engl J Med. 1981 Mar 19;304(12):685-91 - PubMed
  4. Am J Med. 1981 Dec;71(6):1009-26 - PubMed
  5. N Engl J Med. 1980 Oct 16;303(16):897-902 - PubMed
  6. Am J Cardiol. 1981 Feb;47(2):343-56 - PubMed
  7. Proc Natl Acad Sci U S A. 1986 Jun;83(12):4167-71 - PubMed
  8. Lab Invest. 1975 Mar;32(3):339-51 - PubMed
  9. Circulation. 1976 Sep;54(3):365-70 - PubMed
  10. J Am Coll Cardiol. 1989 Mar 1;13(3):755-63 - PubMed
  11. Circulation. 1989 Jul;80(1):198-205 - PubMed
  12. J Clin Invest. 1989 Aug;84(2):517-27 - PubMed
  13. Am J Physiol. 1989 Sep;257(3 Pt 2):H873-82 - PubMed
  14. Circulation. 1988 Jan;77(1):43-52 - PubMed
  15. Circulation. 1989 Jan;79(1):116-24 - PubMed
  16. Circulation. 1989 Jan;79(1):154-66 - PubMed
  17. Circulation. 1986 Mar;73(3):572-8 - PubMed
  18. N Engl J Med. 1986 Oct 23;315(17):1046-51 - PubMed
  19. J Am Coll Cardiol. 1985 Aug;6(2):369-75 - PubMed
  20. FEBS Lett. 1988 Apr 25;231(2):440-4 - PubMed
  21. Circulation. 1988 Mar;77(3):526-34 - PubMed
  22. Circulation. 1988 Sep;78(3):701-11 - PubMed
  23. Nature. 1988 Jan 28;331(6154):363-5 - PubMed
  24. Science. 1986 Apr 4;232(4746):87-90 - PubMed
  25. N Engl J Med. 1986 Oct 9;315(15):913-9 - PubMed
  26. N Engl J Med. 1986 Oct 16;315(16):983-9 - PubMed
  27. Circ Res. 1986 Nov;59(5):568-78 - PubMed
  28. J Am Coll Cardiol. 1987 Jun;9(6):1243-9 - PubMed
  29. Circulation. 1987 Oct;76(4):952-9 - PubMed
  30. J Am Coll Cardiol. 1987 Nov;10(5):998-1006 - PubMed
  31. Circulation. 1986 Jun;73(6):1186-98 - PubMed
  32. J Am Coll Cardiol. 1986 Jul;8(1):245-50 - PubMed
  33. Br Heart J. 1985 Apr;53(4):363-73 - PubMed
  34. N Engl J Med. 1985 Nov 28;313(22):1369-75 - PubMed
  35. Circ Res. 1985 Aug;57(2):223-31 - PubMed
  36. J Am Coll Cardiol. 1986 Mar;7(3):472-8 - PubMed
  37. N Engl J Med. 1983 Aug 18;309(7):396-403 - PubMed
  38. Nature. 1983 Jul 7-13;304(5921):35-9 - PubMed
  39. J Biol Chem. 1984 Apr 25;259(8):5287-94 - PubMed
  40. Am J Cardiol. 1984 Dec 1;54(10):1349-54 - PubMed
  41. Circ Res. 1984 Nov;55(5):642-52 - PubMed
  42. Br Heart J. 1983 Aug;50(2):127-34 - PubMed

Publication Types